Loading market dashboard
Sharp Corporation
SHCAYTechnologyOTCJP
Loading disclosure news
News and disclosures filtered by period, publisher, and event group.
Select a headline to open the full news page in the app.
Novel lead small molecules demonstrate substantial reduction of cholesterol accumulation in NPC patient-derived fibroblasts, with additional data supporting lysosomal health and cellular signaling
Sociedad Química y Minera de Chile posted mixed Q1 results, with revenues beating estimates, while revenues were a sizable miss. The bigger story is the dramatic Y-O-Y rise in revenues and earnings, with long-term fundamentals suggesting that positive financial momentum is likely to continue. I initiated a stock position in SQM, with an intent to buy more on further dips, as a broader strategy to build a core lithium position in my portfolio.
Starz Entertainment remains a compelling "Buy," with strong tailwinds and an attractive valuation despite doubling YTD. Exiting the unprofitable Universal Pay Two deal accelerates STRZ's path to a 20% OIBDA margin by late 2027. Byron Allen's 11% stake and takeover interest provide a potential catalyst, but STRZ is undervalued even without a deal.
United Parks & Resorts Inc. (NYSE:PRKS) reported Monday first-quarter 2026 results that missed analyst estimates on revenue and earnings as unfavorable weather and weaker international visitation pressured attendance.
Virtuix NASDAQ: VTIX executives outlined the company's consumer, enterprise and defense strategy during an investor webinar, while also addressing recent volatility in the company's share price.
The SOX continues to follow its projected historical returns and Elliott Wave path, but the advance may be nearing exhaustion, raising the probability of a retracement toward $10,000.
The AI chip maker has a storied relationship with the $200 mark. They haven't always got on.
The increasingly lofty premium Navitas has garnered since announcing the collaboration with Nvidia on 800V HVDCs underscores a valuation that's gone too far, too fast. Just the past week, Navitas Semiconductor stock gained close to 20% overnight on no particular headline—a potential opportunity to cash in before upcoming earnings volatility. Trading at 44x 2027 sales and with limited visibility into a sustained earnings inflection, NVTS stock remains a high-risk, low-reward pick in the market's favored AI infrastructure trade.
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 17, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces the release of its annual audited consolidated financial statements for the year ended December 31, 2025, and related management discussion and analysis ("MD&A") and annual information form. All dollar figures are in United States dollars, unless otherwise stated.
Sharp Corp. (OTCMKTS:SHCAY - Get Free Report) was the recipient of a significant drop in short interest in March. As of March 31st, there was short interest totaling 6,455 shares, a drop of 57.2% from the March 15th total of 15,099 shares. Approximately 0.0% of the shares of the stock are short sold. Based on
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") announces that following longer-term non-GLP testing the company has decided to advance an alternative compound for its Gaucher and GBA1 Parkinson's programs. The company continues to advance all platform programs including programs for genetic and sporadic forms of neurodegeneration (Progranulin modulators), and a rare neurodegenerative lysosomal disease (Niemann Pick Type C).
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 10, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the fourth tranche (the "Fourth Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Fourth Tranche, the Company issued a total of 200 Notes for aggregate gross proceeds of approximately US$200,000.
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - April 2, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the third tranche (the "Third Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Third Tranche, the Company issued a total of 200 Notes for aggregate gross proceeds of approximately US$200,000.
Falling egg prices hurt the egg producer's top and bottom lines in the third quarter.
The Fear and Greed Index is worth checking in on at moments like this, when the S&P 500 is on the verge of a correction.
With gold about $1,000 from highs and silver $50 off its high, David Stryzewski calls the current metal pullback an "opportunity." That opportunity extends to miners as well, with David calling what he considers low P/E ratios for companies.
Hannover Re delivered strong FY 2025 results, meeting guidance with net income of EUR 2.64 billion and EPS of EUR 21.90. The combined ratio remains below 90%, reflecting disciplined underwriting and robust performance in both P&C and Life & Health segments. HNR1 proposes a EUR 12.50 dividend per share (55% payout), retaining earnings to support future growth and maintain capital strength.
Pittsburgh, Pennsylvania and Toronto, Ontario--(Newsfile Corp. - March 13, 2026) - Sharp Therapeutics Corp. (TSXV: SHRX) (OTCQB: SHRXF) ("Sharp" or the "Company") is pleased to announce that it has closed the second tranche (the "Second Tranche") of its previously announced non-brokered private placement for unsecured convertible notes of the Company (collectively, the "Notes"), in the principal amount of US$1,000 per Note (the "Note Offering"). Pursuant to completing the Second Tranche, the Company issued a total of 200 Notes for aggregate gross proceeds of approximately US$200,000.
Ciena (NYSE:CIEN) is up 8.9% in Tuesday's session, climbing from $318.54 to $346.89 intraday.
Following a careful analysis of the Zacks Transportation Airline industry, we advise buying stocks like LUV, ALGT and CPA.
